Latest Breaking News On - Euronext nasdaq - Page 7 : comparemela.com
Celyad Oncology SA: Celyad Oncology to Host Virtual Research & Development Webinar on July 20th
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Celyad Oncology SA: Celyad Oncology to Participate at the William Blair Biotech Focus Conference 2021
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Celyad Oncology SA: Celyad: Information on the Total Number of Voting Rights and Shares (Article 15 of the Law of 2 May 2007)
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Celyad Oncology SA: Celyad Oncology Announces June 2021 Conference Schedule
Regulatory News:
Celyad Oncology SA (Brussels:CYAD) (Paris:CYAD) (NASDAQ:CYAD) (Euronext Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, today announced that the company plans to participate at the following conferences in June 2021:
Jefferies Virtual Healthcare Conference
Presentation date: Tuesday, June 1, 2021
Time: 11:00 a.m. EST 5:00 p.m. CET
Presenter: Filippo Petti, CEO
Events section of the Celyad Oncology website.
William Blair Company Annual Growth Stock Conference
Dates: Tuesday, June 1 Thursday, June 3, 2021
Presentation date: Wednesday, June 2, 2021
Celyad Oncology SA: Celyad Oncology to Present Data From Phase 1 IMMUNICY-1 Trial of Non-Gene Edited Allogeneic CAR T Candidate CYAD-211 in Relapsed/Refractory Multiple Myeloma at the European Hematology Association Virtual Congress
Initial clinical activity observed, with one confirmed partial response (PR) observed in this low dose (30x10
6 cells per infusion)
Regulatory News:
Celyad Oncology SA (Euronext Nasdaq: CYAD) (Brussels:CYAD) (Paris:CYAD) (NASDAQ:CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T-cell (CAR T) therapies for cancer, today announced that an abstract highlighting initial clinical data from the Phase 1 IMMUNICY-1 trial of CYAD-211 has been accepted for e-poster presentation at the upcoming European Hematology Association (EHA) Virtual Congress 2021